Loading
Diabetes Treatment and Management / Chronic Kidney Disease and Diabetes · Journal article
Clinical Kidney Journal · September 5, 2026
A consensus or society position rather than new primary data.
This review consolidates evidence that incretin-based therapies—single, dual, and triple receptor agonists—offer kidney and cardiovascular protection in type 2 diabetes and CKD beyond glycemic control, with semaglutide established by the FLOW trial as clinically relevant. Emerging dual and triple agonists show promise but require ongoing mechanistic clarification and dedicated outcome trials, particularly regarding the interpretation of kidney function changes during substantial weight loss.
Narrative review. Patients with type 2 diabetes mellitus and chronic kidney disease.
GLP-1 receptor agonists have demonstrated clinically meaningful reductions in cardiovascular events and kidney protection. Semaglutide established as clinically relevant strategy for reducing kidney and cardiovascular risk in T2DM and CKD by FLOW study. Tirzepatide (dual GLP-1/GIP agonist) demonstrated favourable kidney outcomes compared with dulaglutide.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should consider incretin-based therapies as part of cardio-renal-metabolic management in CKD and T2DM, with semaglutide as an established option. However, the long-term renal benefits and mechanisms of multi-receptor modulators require further clarification before broad adoption of dual and triple agonists.
A narrative review synthesizing evidence from multiple trials (FLOW, cardiovascular outcome trials) to position incretin-based therapies within the therapeutic landscape for CKD, without reporting a primary study result or meta-analysis.
As stated by the source record.
Clinicians should consider incretin-based therapies as part of cardio-renal-metabolic management in CKD and T2DM, with semaglutide as an established option. However, the long-term renal benefits and mechanisms of multi-receptor modulators require further clarification before broad adoption of dual and triple agonists.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract The global rise in obesity and type 2 diabetes mellitus (T2DM) has contributed substantially to the increasing burden of chronic kidney disease (CKD), cardiovascular disease, and heart failure, highlighting the need for therapeutic strategies capable of addressing multiple components of the cardio-renal-metabolic axis. Incretin-based therapies have undergone an evolution from glucose-lowering agents to treatments with broad metabolic, cardiovascular, and renal effects. Glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated clinically meaningful reductions in cardiovascular events and have emerged as important therapies for kidney protection. Evidence from cardiovascular and kidney outcome trials, culminating in the FLOW study, has established semaglutide as a clinically relevant strategy for reducing kidney and cardiovascular risk in patients with T2DM and CKD. Beyond single-receptor agonism, the development of dual and triple incretin receptor agonists has expanded the therapeutic possibilities. Tirzepatide, a dual GLP-1/GIP receptor agonist, has demonstrated favourable kidney outcomes compared with dulaglutide, while early studies of the dual GLP-1/glucagon receptor agonist cotadutide suggest additional benefits on albuminuria and cardiorenal risk markers. Retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, has shown promising effects on kidney-related parameters, although the mechanisms underlying observed increases in estimated glomerular filtration rate remain uncertain. Accumulating evidence suggests that incretin-based therapies may exert renoprotective effects through pathways extending beyond glycemic control and weight reduction, including improvements in endothelial function, microvascular integrity, inflammation, fibrosis, and renal hemodynamics. Nevertheless, important questions remain regarding the mechanisms of kidney protection, the interpretation of kidney function changes in the setting of substantial weight loss, and the long-term renal benefits of multi-receptor modulators. Ongoing mechanistic studies and dedicated outcome trials will further define the role of incretin biology in the prevention and treatment of CKD.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.